In addition, the board of directors appointed Dr Spigelman as chairman of the company’s clinical oversight committee as well as a member of the compensation committee.
Dr Spigelman has served as director of R&D for the Global Alliance for TB Drug Development. Dr Spigelman has received a BA in engineering from Brown University and an MD from The Mount Sinai School of Medicine, and is board certified in internal medicine, medical oncology and preventive medicine.
Gary Jacob, president and acting CEO of Synergy, said: “As chairman of Synergy’s clinical oversight committee, Mel will provide critical input to Synergy management on the clinical development of SP-304, Synergy’s drug that recently entered clinical trials to treat gastrointestinal disorders. We are pleased to have Mel join our board and fully expect that his unique experience will be a major asset to Synergy.”